Federation Des Caisses Desjardins Du Quebec Intellia Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.4 Billion
- Q4 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 1,931 shares of NTLA stock, worth $22,264. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,931
Previous 181
966.85%
Holding current value
$22,264
Previous $3,000
633.33%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding NTLA
# of Institutions
335Shares Held
96.1MCall Options Held
1.06MPut Options Held
863K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$145 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$117 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$111 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$60 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$44 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $876M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...